Maurizio Fava

This inventor holds 9 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: The General Hospital Corporation, Nestec S.a.. Active years: 2010-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Maurizio Fava. Retrieved from https://idiyas.com/inventor/maurizio-fava

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 2.3

ph-index = 3

Forward Citations = 16(Granted Patents)

Company Filing History:

7 out of 3,073

The General Hospital Corporation

Years Active: 2010-2023

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11655210 - Compound for improving L-arginine bioavailability (2023-05-23),

2. 9546401 - Assays and methods for selecting a treatment regimen for a subject with depression (2017-01-17),

3. 9540691 - Assays and methods for selecting a treatment regimen for a subject with depression (2017-01-10),

4. 8219419 - System and method for reducing the placebo effect in controlled clinical trials (2012-07-10),

5. 8145505 - System and method for reducing the placebo effect in controlled clinical trials (2012-03-27),

6. 8145504 - System and method for reducing the placebo effect in controlled clinical trials (2012-03-27),

7. 7983936 - System and method for reducing the placebo effect in controlled clinical trials (2011-07-19),

8. 7840419 - System and method for reducing the placebo effect in controlled clinical trials (2010-11-23),

9. 7647235 - System and method for reducing the placebo effect in controlled clinical trials (2010-01-12),

Title: Maurizio Fava: Innovator in Pharmaceutical Sciences

Introduction

Maurizio Fava is a prominent inventor based in Newton, MA (US), known for his significant contributions to the field of pharmaceutical sciences. With a total of 9 patents, Fava has focused on developing innovative compounds and methods aimed at improving health outcomes, particularly in the realm of mental health and bioavailability of essential compounds.

Latest Patents

Fava's latest patents include a compound designed to improve L-arginine bioavailability. This compound is particularly useful for mediating nitric oxide (NO) production, which has various therapeutic applications. Additionally, he has developed novel assays and methods for selecting treatment regimens for subjects with depression. These methods involve identifying nucleic acid polymorphisms and determining expression levels of peripheral biomarkers, which can help in tailoring effective treatment plans for individuals suffering from depression, especially those resistant to standard antidepressant therapies.

Career Highlights

Throughout his career, Maurizio Fava has worked with notable organizations, including The General Hospital Corporation and Nestec S.a. His work has significantly impacted the development of pharmaceutical compositions and treatment methodologies, showcasing his dedication to advancing medical science.

Collaborations

Fava has collaborated with esteemed colleagues such as David Schoenfeld and George Papakostas, contributing to a rich exchange of ideas and innovations in the field of mental health treatment.

Conclusion

Maurizio Fava's innovative work in pharmaceuticals, particularly in improving treatment for depression and enhancing bioavailability of compounds, underscores his role as a leading inventor in the industry. His contributions continue to pave the way for advancements in medical treatments and patient care.

Profile summary based on public USPTO records.